Background Diabetic retinopathy (DR) affects approximately one-third of people diagnosed with diabetes, can be sightthreatening, and generates significant human and economic burden. Over the last 2 decades, newer therapies have emerged, offering significant clinical benefits, however at a cost. Given the scarcity of available budgets, the cost effectiveness of these newer treatments is of vital importance to policy makers. Methods A systematic review was conducted in the PubMed, EMBASE, Cochrane, HEED and CRD databases to find and evaluate economic evaluations assessing the cost effectiveness of alterative DR treatments. Studies were assessed for their eligibility, findings and quality, and are presented in this systematic review. Results Of the 5254 studies retrieved from the literature search, 17 were included in this review. For patients with proliferative DR, when early pars plana vitrectomy was compared with pan-retinal laser photocoagulation, similar cost per qualityadjusted life-year (QALY) was observed between the two. Treatment with either intravitreal ranibizumab (IVR) or intravitreal bevacizumab (IVB) falls within acceptable cost-effectiveness thresholds in the diabetic macular oedema (DMO) population; however, in the non-DMO population, the marginal benefit of IVR or IVB in relation to the marginal cost relative to laser does not justify their use. Among the anti-vascular endothelial growth factor (VEGF) therapies, IVB appears more attractive from an economic point of view due to its lower cost. For patients with DMO, studies indicate that a combination therapy of IVR or IVB with laser and, to a lesser degree, as monotherapy, are cost effective relative to laser monotherapy; IVR plus laser is cost effective relative to laser plus triamcinolone; and laser combined with triamcinolone injections is reportedly more cost effective over IVR for pseudophakic eyes only. Moreover, fluocinolone implants appear cost effective compared with sham implants, or when treating refractory DMO. IVR administered either pro re nata (PRN) or as 'treat and extend' dominated intravitreal aflibercept (IVA) in a few studies. On the other hand, IVR monotherapy or with laser (as well as IVA) does not compare favourably relative to IVB monotherapy or with laser. Conclusions Interpretation of cost-effectiveness data should be treated with caution in this case; details of the therapeutic regimen, such as dosage and frequency, and clinical efficacy of the treatments should be considered in relation to policymaking decisions. Given the scarcity of resources, the ever-increasing significance of health technology assessment, and the substantial differences in the methodologies of the studies presented in this review, there is a pressing need for more advanced and standardised approaches to assessing the effectiveness and cost effectiveness of the emerging anti-VEGF pharmacotherapies for the treatment of DMO.
Introduction
Diabetic retinopathy (DR) is a chronic, progressive, sightthreatening disease of the retinal microvasculature that develops as a result of either type 1 or type 2 diabetes. DR affects approximately one-third of people with diabetes, with one-third of those patients having sight-threatening DR [1] . DR is the leading cause of sight loss in the working age [2] . In patients with diabetes, chronic hyperglycaemia leads to the upregulation of vascular endothelial growth factors (VEGFs) in the retina, resulting, among other events, in angiogenesis (retinal neovascularisation), macular oedema and other inflammatory responses that characterise DR. DR is clinically divided into stages. Non-proliferative DR (NPDR) is the most common form and is clinically detectable in most patients with long-standing diabetes. NPDR may be mild, moderate or severe, while progression to the more sight-threatening proliferative DR (PDR) may also occur. Diabetic macular oedema (DMO) is the most common complication of DR (either NPDR or PDR), where fluid leaks out of blood vessels into the macula, causing swelling and possibly leading to sight loss. Its prevalence can be as high as 25% [3, 4] . A vitreous haemorrhage is a serious, sight-threatening complication of PDR, occurring when new vessels that have abnormally grown in the retina rupture. As the condition progresses, scar tissue may develop, which may pull and distort the retina, causing retinal detachment and vision loss.
Many risk factors are known for the development of DR; duration of diabetes, puberty and pregnancy are nonmodifiable, while hyperglycaemia, systemic hypertension, dyslipidaemia and obesity are known modifiable risk factors. Inflammation, metabolic hormones, oxidative stress and vitamin D deficiency are risk factors that have recently come into play, while the role of genetic predisposition is also acknowledged in relation to the development of DR [1] .
Treatment options for DR and its complications have changed dramatically in recent years as new pharmacotherapies have emerged. The traditional laser therapies have been complemented by the introduction of intravitreal injections of anti-VEGF (ranibizumab, bevacizumab, aflibercept and pegaptanib), corticosteroid injections (triamcinolone or dexamethasone) and sustained delivery vitreous implants (fluocinolone acetonide), which are becoming more popular as first-line treatments. Combinations of laser and the newest pharmacotherapies are also commonly used. Surgical procedures are still the treatment of choice for the most serious complications of PDR (vitreous haemorrhage and retinal detachment), with or without adjunct laser.
Laser
The treatment of PDR has largely relied on the use of panretinal laser photocoagulation, whereby the laser makes small burns that seal the retina and prevent further vessel growth and leakage. The main benefit of laser therapy is vision preservation, not restoration, but it comes with serious ophthalmic adverse effects (foveal burns, visual field defects) that can affect daily activities, such as driving. The traditional treatment option for DMO has also been laser photocoagulation (focal and/or grid), which became the treatment of choice after the results of the Early Treatment Diabetic Retinopathy Study (ETDRS) showed that immediate laser treatment reduced the risk of blindness by 60% at 2 years and allowed recovery of visual acuity (VA) over 3 years [5, 6] . Laser treatment is often used in combination with other treatment modalities.
Anti-Vascular Endothelial Growth Factor (VEGF) Drugs
At present, the anti-VEGF drugs approved by the US FDA, European Medicines Agency (EMA) and the UK-based National Institute for Health and Care Excellence (NICE) for the treatment of DMO are ranibizumab and aflibercept. Bevacizumab is also used off-licence by retina specialists for the treatment of DMO and has a lower cost than the other anti-VEGF drugs. A number of high-quality clinical studies have shown that treatment with these anti-VEGF drugs is clinically more effective than laser, while they also come with minimal systemic and ophthalmic adverse effects [7] [8] [9] [10] [11] [12] [13] [14] . Intravitreal anti-VEGF drugs come at a high cost and need to be administered frequently, posing a significant financial burden on healthcare systems and patients [15, 16] . Intravitreal anti-VEGF drugs are delivered according to two regimens. Under the pro re nata (PRN) approach, patients are observed and treated only after clinical signs of disease development. The 'treat and extend' approach allows a gradual increase in treatment intervals, aimed at maximising the treatment and visit intervals; the extension of intervals is patient-specific. The PRN approach has been deemed clinically effective with ranibizumab 0.5 mg in the long-term RESTORE and DRCR.net (protocol I) studies [9, 12, 17, 18 ].
Corticosteroids
Triamcinolone is a corticosteroid suspension that has been used to treat other ophthalmic pathologies. In the US, it is licensed for intraocular use for ocular inflammatory conditions. Although it is not licensed for treating DMO, it has been used for that purpose. Although triamcinolone has been shown to temporarily improve VA in eyes with DMO [19] , it has failed to clinically compare favourably to laser therapy [20] . It has a high rate of complications (rise in intraocular pressure [IOP] and accelerated cataract formation) and is reserved for DMO refractory to other therapies [21, 22] .
Dexamethasone biodegradable implants mediate controlled release of dexamethasone for up to 6 months, although data and anecdotal clinical experience show that its clinical efficacy may be limited to 4 months. Dexamethasone is licensed for the treatment of DMO and has demonstrated clinical efficacy [23, 24] , but higher rates of cataract and a rise in IOP have been reported [24] [25] [26] .
The fluocinolone intravitreal non-biodegradable implant contains fluocinolone acetonide, a corticosteroid, and is licensed in the US and the UK for 'the treatment of vision impairment associated with chronic DMO considered insufficiently responsive to available therapies' [27] . It is an intraocular slow-release system that allows a controlled drug delivery over 36 months, having the best longevity of currently available treatment options for DMO. The implant has high rates of steroid-induced ocular comorbidities (elevated IOP and cataract progression) [28] .
Ocular Surgery
Pars plana vitrectomy is a surgical procedure performed to remove the vitreous filling the eye cavity. Vitrectomy is performed to either clear the vitreous in the case of a vitreous haemorrhage, or to provide better access to the retina and allow for the removal of scar tissue, application of laser, reattachment of a detached retina, or the treatment of other retinal pathologies. Vitrectomy requires specialist surgical skills and incurs various costs inside and outside the operating room.
As the diabetic population has been projected to increase [29] [30] [31] , the population with DR is also expected to rise by a staggering 50-80% over the next two decades [32] . DR services will therefore generate additional operational and financial burden. In the UK for instance, the cost burden of DM to the National Health Service (NHS) will reportedly double between 2010 and 2035 [33] . This burden comprises the cost of treatment services and managing complications, as well as indirect social and productivity costs associated with DR (comorbidities and/or need for care), which also need consideration. Notably, patients of working age with DMO have shown a complicated comorbidity profile and high burden on healthcare consumption [16] .
As expected, the use of novel pharmacotherapies is costly. With the increasing burden that diabetes, DR and DMO place on healthcare systems, the cost effectiveness of treatments for these conditions is a major factor that decision makers must consider before drafting health policies. The ultimate aim is to allocate resources rationally and efficiently. This article presents a systematic review of the literature on the cost effectiveness of current treatments for DR and its complications (DMO, vitreous haemorrhage).
Methods
This review was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria [34] .
Search Strategy
The PubMed, EMBASE, Cochrane, HEED and CRD electronic databases were searched from inception until July 2018. Searches were conducted by using predetermined keywords. Studies were included if they had been peerreviewed and were full economic evaluations. The searches were complemented by hand-searching the bibliographies of included studies. The full search strategy is shown in ESM Appendix 1.
Inclusion and Exclusion Criteria
Studies were included in this systematic review if they were original full economic evaluations (i.e. cost-effectiveness, cost-utility, etc.) of DR treatment and the full text was available in English, but studies that were incomplete in terms of the presented data, previously published systematic reviews, abstracts, poster presentations, case reports, letters, comments, editorials, or other types of articles, such as clinical, pharmacodynamic, or pharmacokinetic studies, were excluded.
Analysis Process
All studies were initially evaluated based on their titles and abstracts. Studies not fulfilling the above inclusion criteria were excluded, and the full texts of the remaining studies were retrieved for further assessment. References were checked both automatically and manually to remove duplicates. The remaining full texts were considered for final appraisal.
Data Extraction and Data Synthesis
Data extraction included the following information: authors, year of publication, type of analysis and modelling techniques, reference country of the study, comparators assessed, condition treated, perspective of the analysis, time horizon, population studied, costing year, main study outcomes considered, and author conclusions. Data were tabulated in a standardised form.
Quality Assessment
The quality of the identified studies was assessed using the Quality of Health Economic Studies (QHES) instrument [35] . Due to the lack of an established interpretation of the QHES score, an arbitrary score of 70 was used as the cut-off for classifying the quality of the included studies as 'good'. Quality assessment was performed by the authors without masking of the study identifiers.
Results
The literature search of the selected databases revealed 5254 abstracts (PubMed 1449, Embase 2033, Cochrane 1313, and CRD 459, including DARE, NHS EED, HTA). After duplicates were removed, 1915 abstracts remained for evaluation. A total of 47 records were assessed for eligibility. One reference was identified via hand-searching the bibliographies of the included studies. In total, 30 items were excluded [21 conference presentations, 1 editorial, 1 health technology assessment report, 1 systematic review previously published, 2 clinical applications of cost analyses, 1 healthcare resource use and associated financial costs before and after specific treatment, 1 quality-of-life (QoL) article, 1 economic impact study, and 1 study on the treatment of retinal detachment in eyes with co-existing DR]. A total of 17 peer-reviewed publications were included in this review (1 cost-effectiveness study, 15 cost-utility studies and 1 cost-minimisation analysis based on real-world data). The selection process is shown in Fig. 1 , and a summary of the main characteristics of the included studies is shown in Table 1 .
The quality assessment results of the studies using the QHES tool is shown in ESM Appendix 2. With the exclusion of one cost-minimisation analysis (which scored 49 on the QHES tool), the remaining 16 studies were of good quality (range 77-99). All studies presented their objective in a clear manner and justified their conclusions/recommendations based on their results. Of the 17 studies, 16 declared their funding source [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] .
Proliferative Diabetic Retinopathy
A total of three cost-utility analyses reported on the treatment of PDR [42, 51, 53] . One study used a Markov-style model [42] , one used a decision analysis model [53] and one study was based on trial data [51] . The time horizons of the studies varied, ranging from 2 years to a lifetime. All studies included direct costs and adopted the payers' perspective. One study reported the costs of diagnostic/therapeutic procedures and costs for the treatment of related adverse events (AEs) [51] , and two studies reported professional fees, and facility and non-facility costs [42, 53] . All three studies were conducted in the US and reported treatment cost and quality-adjusted life-years (QALYs) [42, 51, 53] . Nonetheless, only one of these studies [51] reported incremental cost-effectiveness ratios (ICERs) in the form of incremental cost per QALY gained (iCpQ). The other two studies were conducted by the same team. One was an extension of the other, but both reported average cost per QALY figures, which is not the proper way to compare alternatives from a cost-effectiveness perspective [42, 53] . One study has also reported results on cost per line saved and cost per line-year saved (the cost per lines saved divided by life expectancy of the patient group studied) [43] .
More specifically, one study [51] considered the cost of treating PDR with intravitreal ranibizumab (IVR) injections compared with laser, based on data from the Diabetic Retinopathy Clinical Research Network RCT (DRCRN, protocol S). Different outcomes were reported depending on the presence or absence of DMO. For patients with DMO at baseline, the IVR iCpQ versus laser fell within the $50,000-$150,000 range that is commonly cited in the US as being cost effective, with an iCpQ of $55,568. Treating PDR without associated DMO with IVR was not cost effective compared with laser photocoagulation, with an iCpQ of $662,978; in this case, laser is preferred.
Another study [42] compared the cost effectiveness and cost utility of treating PDR patients with laser compared with IVR and IVB, using published resource use and outcome data from the DRCRN, to construct a Markov style model. It was concluded that although both treatment options fell below the accepted iCpQ upper limit, laser was less expensive than IVR over 2 years (laser cost per QALY $7988; IVR cost per QALY $19,150). The same study substituted IVR for IVB and concluded that it could yield 69% facility reduction of costs per QALY over IVR (2-year IVB cost/QALY $5864). The study also reported lifetime estimates based on the premise that anti-VEGF therapy will be administered during a lifetime, beyond the initial period of 2 years, on a biannual basis. The lifetime cost/QALY was estimated at $24,005 for laser, $164,360 for IVR and $47,915 for IVB. On this basis, it concluded that IVR may not be below conventional acceptance thresholds. Nonetheless, this study needs some consideration as it does not report the incremental cost per QALY ratio, but does report the average cost per QALY ratio, with the latter not being a correct comparison measure.
The same data and study were further used to compare early vitrectomy with laser and IVR in patients with PDR (and certain complications of PDR in the case of vitrectomy), but without DMO, using a cost-utility model spanning a lifetime [53] . Vitrectomy showed similar costs as laser per QALY, in the short-and long-term ($181,144 and $63,942, compared with $163,988 and $61,695 for laser, respectively). IVR was not satisfactory, with high ratios at 2 years and lifetime ($436,992 and $338,348, respectively). Notably, this study also used an average approach rather than an incremental approach, and the results need to be viewed from that perspective. Surprisingly, this study gave quite different results to the previous study in relation to the common therapies considered in both. Records identified through database searching
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Diabetic Macular Oedema
This review included 13 studies focusing on DMO; 11 costutility studies [36, 38-41, 43, 46, 48-50, 52 ], 1 cost-effectiveness study [44] , and 1 cost-minimisation study [47] . The majority of the studies (10) used a Markov model and were conducted in the US (7) or the UK (4). There was variability in terms of the time horizons considered as four studies had a lifetime horizon, with the remaining studies varying from 2 to 40 years. The therapies considered also varied between the different studies. The results are presented below for each alterative therapy option.
Laser
One of the earliest included studies compared grid laser photocoagulation with no treatment, for DMO, and found a QALY gain of 0.236 and an incremental cost per QALY of $3655; grid laser photocoagulation was hence shown to be very cost effective [38] . However, another study demonstrated lifetime costs of laser treatment and QoL similar to no treatment [40] . In a few studies, laser monotherapy has been shown to be inferior in relation to IVR alone or IVR plus laser [40, 41, 43] . In particular, a study in Canada resulted in an iCpQ for IVR vs. laser at CAN$24,494, and IVR plus laser vs. laser at CAN$36,414 [43] . A study in the UK resulted in an iCpQ of IVR vs. laser at £24,028, and IVR plus laser vs. laser at £36,106, although the later was marginally above the established threshold [41] . A study in the US estimated the iCpQ of IVR plus laser at $12,410 relative to laser plus triamcinolone at 1 year, and $26,467 over a lifetime [40] . Another US study estimated the iCpQ of IVR plus laser vs. laser at $89,903, and that of intravitreal bevacizumab (IVB) plus laser vs. laser at $11,138. In the same study, laser plus triamcinolone was dominated by laser [36] . Hence, laser may be preferred relative to IVR plus laser only for willingness-to-pay (WTP) thresholds below $50,000/QALY [36] . Finally, a study in the UK comparing IVB with macular laser treatment for DMO estimated an iCpQ of £51,182, outside the accepted NICE WTP range of £20,000-£30,000 [48] . However, the latter results need to be seen with caution due to an underrepresentation of the VA benefits of the IVB intervention.
Corticosteroids
Two studies compared the fluocinolone non-biodegradable implant with a sham implant [46] and with no treatment [47] . In a study relating to the US system, the fluocinolone implant was cost effective in a cohort of carefully selected patients, thus minimising AEs, with an expected iCpQ of $38,763 from a societal perspective [46] . Cost savings were also demonstrated when patients with refractory DMO were switched to fluocinolone (£2606), but less so when taking into account treatment for raised IOP (£1064), a common AE [47] . Triamcinolone combined with laser has been compared with a battery of intravitreal anti-VEGF medications and with focal laser (FL) alone [36, 40, 44] . In one study undertaken in the US, triamcinolone plus laser has been shown to be dominated when compared with laser and intravitreal anti-VEGF injections, mainly due to the AEs related to its use and the cost of managing them [36] . In another US study, triamcinolone monotherapy showed limited gains in QALYs compared with other treatments (for bilateral disease and over a lifetime) and is reportedly inferior to no treatment due to its AEs, but has similar lifetime costs as no treatment [40] . In particular, lifetime laser plus triamcinolone was the least effective and costly strategy, and the iCpQ of laser plus IVR was $26,467, which makes it preferable as it represents good value for money. In yet another US study, triamcinolone plus laser did not compare favourably as the incremental cost per letter of sham injection plus laser vs. triamcinolone plus laser was estimated at $393 [44] . Moreover, the iCpQ of IVR vs. T at 10 years was estimated at $87,584; however, it has been shown that it may be the most cost-effective first-line treatment for pseudophakic eyes at low risk of developing glaucoma [44] . In this group, sham injection plus laser and IVR plus laser were dominant, and the ICER for triamcinolone plus laser vs. IVR plus deferred laser was $14,690/ letter, although the study did not convert it into QALYs.
Anti-VEGF Drugs
IVR has been compared with sham injections and showed QALY gains for unilateral and bilateral treatment. A US study showed that when taking into account direct, indirect and societal costs, IVR confers significant patient value gain, as well as financial value to patients, society, and public and private insurers. From a societal perspective, the iCpQ was − $30,807, $4587 from a direct medical/non-medical perspective, and $56,336 from a direct medical perspective only [49] .
A number of different treatment regimens, dosages, timings, combinations with laser, and frequency of intravitreal injections have been assessed in terms of their cost effectiveness. In particular, IVR has shown fewer costs, more QALYs gained, and better clinical outcomes than intravitreal aflibercept (IVA) in both Greek and UK settings [39, 52] . Specifically, in Greece, IVR was dominant against IVA, with a net monetary benefit (NMB) of between €1278 and €3984 at a WTP threshold of €25,000, depending on the regimen used [52] . Similarly, in the UK, IVR has shown an NMB of between £3934 and £6768 at a WTP of £20,000, with reduced lifetime costs over IVA, and does so under both a PRN and a 'treat and extend' regimen [39] . In a US study comparing four different treatment options (sham injection plus laser, IVR plus prompt laser, IVR plus delayed laser, triamcinolone plus laser) 'IVR plus deferred laser' could meet accepted standards of cost effectiveness, assuming the VA benefits were long-term and no additional injections were needed beyond 2 years [44] . In particular, IVR plus prompt laser vs. sham injection plus laser had an ICER of $5943/ letter, and $20/letter for IVR plus deferred laser vs. IVR plus prompt laser [44] . In the UK, IVR monotherapy was reported to have an iCpQ vs. laser of £24,028 and was 64% likely to be cost effective at the £30,000 WTP threshold. IVR in combination with laser had an iCpQ of £36,106 vs. laser and was 42% likely to be cost effective at the £30,000 WTP threshold [41] . A similar comparison in Canada showed IVR monotherapy had a lower iCpQ than combination therapy with laser (CAN$24,494 vs. CAN$36,414, respectively), relative to laser monotherapy. Moreover, in the study by Pershing et al., IVR monotherapy achieved a marginally lower QALY gain than IVR combined with laser [40] . There was a small difference in QALY gains between monotherapy and combination therapy (0.03 QALYs) and a difference of £1240 in costs. The authors argued that laser treatment of patients receiving IVR monotherapy prior to trial participation may have augmented the benefits shown for IVR monotherapy.
IVB demonstrates the lowest cost of the available anti-VEGF drugs. In a US study, the iCpQ of IVB plus laser vs. laser was $11,138, compared with $89,903 for IVR plus laser, when the need for additional treatment beyond the 2-year time horizon was taken into account [36] . Moreover, in another US study, IVB plus laser has been shown to be more cost effective than IVR plus laser [40] . In particular, IVR plus laser had an iCpQ of $3.5 million vs. IVB plus laser. Another study indicated that at 10 years, IVA had an iCpQ of $349,000 and IVR of $603,000 compared with IVB. Furthermore, IVA had an iCpQ of $203,000 compared with IVR. IVA and IVR treatment costs would need to be significantly reduced for use in patients with decreased vision to reach the cost-effectiveness threshold of $100,000/QALY (69% and 80%, respectively) [50] .
Vitreous Haemorrhage
One study looked into the cost-utility of early versus deferred vitrectomy for the treatment of vitreous haemorrhage in DR [37] . That study was conducted in the US using a Markov model for a hypothetical group of patients, with a 55-year time horizon. The study, conducted from the perspective of a for-profit insurer, took into account only direct costs and reported 0.41 QALYs gained over the lifespan of a hypothetical patient, with a cost of $1910 per additional QALY gained from early vitrectomy compared with deferred vitrectomy.
Discussion
Diabetes, DR, and their complications are a significant burden on healthcare systems, society and patients themselves globally. The annual DR treatment cost has been estimated between €113.0 and €397.0 per patient in France and between €177 and €1564 per patient with DR or DMO in Spain [54, 55] . The estimated first year annual hospital inpatient cost of unilateral diabetes-related blindness is £4370 per patient in the UK, and £2945 for each subsequent year (1998) [56] , while diabetes-related blindness costs the US $500 million annually [57] . Hence, effective management is pivotal and justifiable on humanistic and economic grounds. This systematic review focused on the cost effectiveness of treatments for DR and its complications. The studies included were mainly conducted in the US and the UK. The reported studies are difficult to compare due to the heterogeneity of their study designs, outcome measures, cost estimates, perspective, time horizons, and therapeutic approaches used. Nonetheless, some general conclusions can be drawn.
For the treatment of PDR, only three studies have evaluated the cost effectiveness of laser, IVR, IVB, and early vitrectomy in the US. The benefits of treatment for PDR are clinically irrefutable. Most studies consider laser the reference treatment for the PDR population. When early vitrectomy is compared with laser, the former shows similar cost per QALY as the latter, according to the study by Lin et al. [53] . Treatment with either IVR or IVB falls within acceptable cost-effectiveness thresholds in the US, mainly in the DMO population; however, in the non-DMO population, the marginal benefit of IVR or IVB in relation to the marginal cost relative to laser does not justify their use [42, 51] . Among the two anti-VEGF therapies, IVB appears more attractive from an economic point of view due to its lower cost. Finally, the single study included in this review that focused on the treatment of vitreous haemorrhage indicates that early vitrectomy is cost effective compared with deferred intervention [37] .
There were more studies conducted relating to DMO treatment, with great variability in their methodology and results. In this case, laser on its own, or with other therapies, is often the standard of care in many evaluations. Studies in the UK, US and Canada indicate that therapy with IVR or IVB with laser, and, to a lesser degree, as monotherapy, may be cost effective relative to laser monotherapy [36, 41, 43] . Only one study in the UK demonstrated the opposite, but this may be due to methodological issues [48] . Moreover, a study in the US has shown IVR plus laser is cost effective relative to laser plus triamcinolone [40] . However, laser combined with triamcinolone injections is reportedly more costly and more effective. It may also be cost effective over IVR for pseudophakic eyes only (eyes that have undergone cataract removal and insertion of an intraocular lens) [44] ; in this group, other therapies are being dominated. Moreover, fluocinolone implants appear highly cost effective compared with no treatment, sham implants, or when treating refractory DMO [46, 47] . Notably, because of complications, triamcinolone monotherapy for DMO is inferior to no treatment [40] .
Comparisons among intravitreal anti-VEGF agents are not simple as different therapeutic regimens and clinical protocols have been used. IVR administered either PRN or as 'treat and extend' dominated IVA in three studies in the UK and Greece [39, 50, 52] . On the other hand, IVR monotherapy (as well as IVA) may not be cost effective relative to IVB [50] . Moreover, in the US, IVR plus laser was not cost effective relative to IVB plus laser [40] . In addition, in another US study, IVB combination therapy with laser appears to have a much lower ICER relative to laser alone than IVR combined with laser [36] . Interestingly, IVR combination therapy with laser dominates IVR monotherapy, when both 0.5 and 0.3 mg of ranibizumab are used [40] .
Clinical Comment
When assessing the cost effectiveness of anti-VEGF injections, the doses and number of injections administered may make a significant difference. A number of studies included in this review used doses that do not reflect current guidelines. IVR has been compared with other therapies when 0.3 mg were administered, but a 0.5 mg dose is currently commonly used. In the included studies, IVA has been compared as 2 or 0.5 mg, and IVB at a fixed dose of 1.25 mg. Furthermore, Protocol I stipulated an average of 10 IVR injections over 2 years [9] , with IVR remaining cost effective as monotherapy (ICER below £30,000 per QALY gained) for up to 13 injections [41] . Similarly, IVR has been found cost effective in a US study where a maximum of 12 injections were delivered over 2 years [51] . The number of injections and time horizon may be a cost driver and may also be related to disproportionate differences between IVB and IVR. For example, the iCpQ of IVR vs. laser was £24,028 in one study, with an average of 10 injections over 2 years [41] , while in another study, the iCpQ of IVB vs. laser was found to be £51,182 (assuming 21 injections over 4 years), despite its significantly lower cost [48] .
Interpretation of cost-effectiveness results requires caution, as well as understanding each treatment's clinical effectiveness and the details underpinning the treatment regimens compared in each study. Although IVA has shown VA benefits compared with IVB or IVR, these do not reflect significant QoL improvements [50] . On the contrary, IVB, currently used off-label for ocular pathologies, may have shown some weaknesses from a clinical perspective, e.g. lower ETDRS letter improvement and a decrease in the central subfield thickness [58] . However, IVB is consistently cost effective and appears as the treatment of choice for developed and developing countries, in what is still an offlabel use [59] . Recent legislative changes have allowed policy makers in the UK to offer patients IVB for the treatment of wet age-related macular degeneration, which is expected to result in significant cost savings for the NHS [60] .
Limitations
This systematic review has certain limitations. The restriction to full texts published in English may have excluded some studies written in other languages, and the inclusion of only peer-reviewed publications will have inevitably excluded a significant amount of gray literature studies. Some of these excluded studies discussed the cost effectiveness of pharmacotherapies that have not been discussed in this review. However, the inclusion of gray literature would not have allowed for the assessment of the methodological quality of the studies and could have subsequently compromised the accuracy of the presented data.
Conclusions
A battery of newer pharmacotherapies is available to clinicians, allowing them to tailor treatment to the clinical characteristics of patients and the funding available to them. The results of the studies included in this review show that despite the methodological differences, the newer intravitreal anti-VEGF drugs are cost effective, either as monotherapy or in combination with laser, for the treatment of DMO, and in combination with laser for the treatment of PDR with associated DMO. Similarly, the newer fluocinolone implant seems to have overcome the clinical weaknesses of earlier corticosteroid pharmacotherapies, while still being cost effective. Laser monotherapy might still be the most cost-effective treatment for PDR in the absence of DMO and early surgical intervention is cost effective for the complications of DR.
Cost effectiveness is a vital factor in deciding healthcare policies; the availability and licensing of certain pharmacotherapies need to be considered by policy makers. Given the scarcity of resources, the ever-increasing significance of health technology assessment, and the substantial differences in the methodologies of the studies presented in this review, there is a pressing need for more advanced and standardised approaches to assessing the effectiveness and cost effectiveness of the emerging anti-VEGF pharmacotherapies for the treatment of DMO (brolucizumab, abicipar pegol, conbercept).
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